Clinical Trial Update: Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases [Phase 4]

View source ↗

Summary

Phase 4 study evaluating rituximab for Anti-Vimentin Antibody-associated Diseases, including Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-vimentin Antibody-associated Diseases
• Meningoencephalomyelitis Associated with Vimentin Igg Autoantibodies

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Xuanwu Hospital, Beijing | Conditions: Anti-Vimentin Antibody-associated Diseases, Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies | Phase 4 | Status: NOT_YET_RECRUITING